File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.3892/ol.2019.10479
- Scopus: eid_2-s2.0-85069828980
- PMID: 31423287
- WOS: WOS:000476990900132
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Curcumin enhances cisplatin sensitivity by suppressing NADPH oxidase 5 expression in human epithelial cancer
Title | Curcumin enhances cisplatin sensitivity by suppressing NADPH oxidase 5 expression in human epithelial cancer |
---|---|
Authors | |
Keywords | Cancer Cisplatin Curcumin NADPH oxidase 5 Sensitivity |
Issue Date | 2019 |
Publisher | Spandidos Publications. The Journal's web site is located at http://www.spandidos-publications.com/ol |
Citation | Oncology Letters, 2019, v. 18 n. 2, p. 2132-2139 How to Cite? |
Abstract | Cisplatin‑based chemotherapy regimens serve a pivotal role in human cancer treatment. Nevertheless, treatment failure may occur if the cancer is inherently resistant to cisplatin or acquires a resistant phenotype during the course of treatment. Although cisplatin resistance can hinder the efficacy of cisplatin treatment for human cancer, the underlying mechanism remains poorly understood. The current study established a cisplatin‑resistant human epithelial cancer cell line. Notably, differential upregulation of NADPH oxidase 5 (NOX5) was identified in this resistant cell line. Furthermore, cisplatin treatment induced cancer cells to express NOX5 and cells that overexpressed NOX5 exhibited greater resistance to cisplatin via the activation of Akt. Treatment with curcumin may suppress NOX5 expression in cancer cells and enhance sensitivity to cisplatin treatment. In a xenograft model, a combined regimen of cisplatin with low‑dose curcumin significantly reduced malignant tumor growth. These data demonstrate that curcumin has a chemosensitizing effect on cisplatin‑resistant epithelial cancer types. Therefore, the use of curcumin in addition to a cisplatin‑based treatment regimen may improve treatment outcomes in human patients with epithelial cancer. |
Persistent Identifier | http://hdl.handle.net/10722/277245 |
ISSN | 2023 Impact Factor: 2.5 2023 SCImago Journal Rankings: 0.644 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | CHEN, S | - |
dc.contributor.author | Gao, W | - |
dc.contributor.author | ZHANG, MJ | - |
dc.contributor.author | Chan, JYW | - |
dc.contributor.author | Wong, TS | - |
dc.date.accessioned | 2019-09-20T08:47:21Z | - |
dc.date.available | 2019-09-20T08:47:21Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | Oncology Letters, 2019, v. 18 n. 2, p. 2132-2139 | - |
dc.identifier.issn | 1792-1074 | - |
dc.identifier.uri | http://hdl.handle.net/10722/277245 | - |
dc.description.abstract | Cisplatin‑based chemotherapy regimens serve a pivotal role in human cancer treatment. Nevertheless, treatment failure may occur if the cancer is inherently resistant to cisplatin or acquires a resistant phenotype during the course of treatment. Although cisplatin resistance can hinder the efficacy of cisplatin treatment for human cancer, the underlying mechanism remains poorly understood. The current study established a cisplatin‑resistant human epithelial cancer cell line. Notably, differential upregulation of NADPH oxidase 5 (NOX5) was identified in this resistant cell line. Furthermore, cisplatin treatment induced cancer cells to express NOX5 and cells that overexpressed NOX5 exhibited greater resistance to cisplatin via the activation of Akt. Treatment with curcumin may suppress NOX5 expression in cancer cells and enhance sensitivity to cisplatin treatment. In a xenograft model, a combined regimen of cisplatin with low‑dose curcumin significantly reduced malignant tumor growth. These data demonstrate that curcumin has a chemosensitizing effect on cisplatin‑resistant epithelial cancer types. Therefore, the use of curcumin in addition to a cisplatin‑based treatment regimen may improve treatment outcomes in human patients with epithelial cancer. | - |
dc.language | eng | - |
dc.publisher | Spandidos Publications. The Journal's web site is located at http://www.spandidos-publications.com/ol | - |
dc.relation.ispartof | Oncology Letters | - |
dc.subject | Cancer | - |
dc.subject | Cisplatin | - |
dc.subject | Curcumin | - |
dc.subject | NADPH oxidase 5 | - |
dc.subject | Sensitivity | - |
dc.title | Curcumin enhances cisplatin sensitivity by suppressing NADPH oxidase 5 expression in human epithelial cancer | - |
dc.type | Article | - |
dc.identifier.email | Gao, W: weigaoi@hku.hk | - |
dc.identifier.email | Chan, JYW: jywchan1@HKUCC-COM.hku.hk | - |
dc.identifier.email | Wong, TS: wongtsa@hkucc.hku.hk | - |
dc.identifier.authority | Gao, W=rp02222 | - |
dc.identifier.authority | Chan, JYW=rp01314 | - |
dc.identifier.authority | Wong, TS=rp00478 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.3892/ol.2019.10479 | - |
dc.identifier.pmid | 31423287 | - |
dc.identifier.pmcid | PMC6607287 | - |
dc.identifier.scopus | eid_2-s2.0-85069828980 | - |
dc.identifier.hkuros | 305721 | - |
dc.identifier.volume | 18 | - |
dc.identifier.issue | 2 | - |
dc.identifier.spage | 2132 | - |
dc.identifier.epage | 2139 | - |
dc.identifier.isi | WOS:000476990900132 | - |
dc.publisher.place | Greece | - |
dc.identifier.issnl | 1792-1074 | - |